JIB-04, an inhibitor of Jumonji histone demethylase as a potent antitubercular agent against Mycobacterium tuberculosis.

Publication date: Nov 19, 2024

The increasing drug resistance of Mycobacterium tuberculosis (Mtb), coupled with the limited availability of effective anti-tuberculosis medications, poses significant challenges for the management and treatment of tuberculosis (TB). Globally, non-tuberculous mycobacteria (NTM) infections are increasing, with Mycobacterium avium complex and Mycobacterium abscessus (Mab) being the most common in labs and having few treatment options. There’s an urgent need for innovative therapies against Mtb and NTM that are effective and have minimal side effects. The study evaluated the in vitro efficacy of JIB-04, a Jumonji histone demethylase inhibitor, against Mtb, Mab, and multidrug-resistant (MDR) clinical isolates using the minimum inhibitory concentration (MIC) assay. We also determined the minimum bactericidal concentrations (MBCs) of JIB-04 against the H37Rv and H37Ra strains. A time-kill assay was performed to assess the comparative efficacy of JIB-04 and rifampicin against H37Ra. Additionally, the study investigated the impact of JIB-04 on biofilm formation and the persistence of H37Ra over extended periods. Our findings demonstrated a substantial inhibitory effect of JIB-04 on the growth of Mab, Mtb, and MDR clinical isolates. JIB-04 showed bactericidal effects at twice the MIC, outperforming rifampicin in reducing viable cell counts over 8 days. It showed moderate cytotoxicity to mammalian cells but effectively inhibited biofilm formation. In our anoxia model, JIB-04 induced a significant, concentration-dependent reduction in bacterial load. JIB-04 is a promising candidate for the treatment of MDR tuberculosis.

Concepts Keywords
Avium Animals
Bactericidal Antitubercular Agents
Biofilm Antitubercular Agents
Promising Humans
Tuberculosis Microbial Sensitivity Tests
Multiple-drug resistance
Mycobacterium abscessus
Mycobacterium avium Complex
Mycobacterium tuberculosis
Mycobacterium tuberculosis
Rifampin
Rifampin
Spiro Compounds
Spiro Compounds
Thiazines
Thiazines
Tuberculosis, Multidrug-Resistant

Semantics

Type Source Name
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH infections
drug DRUGBANK Methyl isocyanate
disease IDO assay
disease IDO bactericidal
drug DRUGBANK Rifampicin
pathway KEGG Biofilm formation
disease IDO cell
disease MESH anoxia
disease MESH MDR tuberculosis

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *